Avitide is dedicated to advancing our partners clinical pipelines and commercial manufacturing processes with a rapid, exclusive, and enabling affinity purification platform technology.
Delivery of a high yield, high purity molecule-specific affinity resins in 3 months or less. Speed to identify an efficient purification process to reach the clinic faster, and to scale quickly afterwards.
Beyond capture – bioprocess affinity chromatography resins that can select for product quality attributes or product related isoforms. Affinity ligand selectivity that can dial in specific product profiles for biosimilars, and affinity resins that can bind and elute under gentler conditions than Protein A.
A proactive and robust approach to prevent unpredictable purification challenges from microbial, insect, and mammalian production systems, and from the introduction of upstream process changes/improvements. Avitide enables a monoclonal antibody-like purification process for any biopharmaceutical.
Every affinity resin discovery campaign is exclusive to our Partners. Partners receive an exclusive license to key bioprocess technology and intellectual property for the manufacture of biological therapeutics, biosimilars, gene therapies, serum products, and vaccines. A clear strategic advantage and purification platform for companies with diverse biologics and vaccines portfolios.
Avitide's industry-leading 3-month service and proprietary affinity resin discovery and development technology offers unparalleled speed, performance, and product resolution that will enable bioprocess programs to define a cost-effective affinity purification solution for any class of biopharmaceutical.
On-demand, molecule-specific affinity purification enables high yield and high purity purification processes for gene therapy vectors, vaccines, bispecific antibodies, and therapeutic proteins. Let's move beyond capture: Avitide delivers novel affinity resins that can select for product quality attributes to improve upon drug product purity, safety, and potency.
Avitide affinity resins are more cost-effective and scalable compared to other affinity ligand and resin manufacturing technologies. The proprietary peptide-based affinity ligands and scaffolds deliver high dynamic binding capacity and cleaning/sanitization stability. To ensure line of sight to commercial resin, affinity ligand manufacturability is assessed very early in the affinity resin discovery and development process (usually within 6 weeks) so that every affinity purification solution delivered is ready to meet the rigors of biopharmaceutical manufacturing.
Avitide is happy to share case studies on the platform’s capabilities and discuss where we can deliver affinity purification solutions for your clinical and commercial biopharmaceutical programs, life-cycle management projects, and process analytical technology needs
COMMITTED TO DEVELOPING LONG-TERM AND STRATEGIC RELATIONSHIPS.
Avitide Partners define the success metrics for affinity separation performance and drug product purity and quality for every technology that Avitide delivers. Avitide’s industry-leading platform provides a breadth of affinity separation capabilities to deliver novel and exclusive affinity purification solutions towards a diverse array of biopharmaceutical molecules and separation challenges.
Avitide is committed to building long-term and strategic relationships with its Partners. Every campaign begins with full transparency and alignment of Avitide’s Affinity Ligand Discovery and Affinity Resin Development activities to deliver separation solutions that accomplish our Partners’ time, cost, and separation goals.
Avitide thrives on a data-driven culture. That culture is demonstrated in every campaign through the delivery of multiple touch points that allow data-driven decision making by our Partners.
Speed is service. Avitide delivers an industry-leading affinity purification discovery service to achieve high performance and partner-exclusive affinity separation products quickly and within relevant bioprocess timelines. Avitide also offers its existing Partners flexible Expanded Access Arrangements to enable streamlined, on-demand affinity purification solutions for diverse biologics and vaccine portfolios.
WE HAVE A PASSIONATE TEAM THAT ENJOYS TACKLING CHALLENGING PROBLEMS.
LET US KNOW HOW WE CAN HELP.
Call Us 603.965.2100
Visit Us 16 Cavendish Court, Lebanon, NH 03766
AVITIDE, INC., SECURES SERIES C FINANCING TO EXPAND ON-DEMAND BIOPHARMACEUTICAL AFFINITY PURIFICATION PLATFORM AND ACHIEVE PROFITABILITY NEOMED...
AVITIDE INC. SECURES SERIES A FINANCING TO COMMERCIALIZE NOVEL BIOPHARMACEUTICAL AFFINITY PURIFICATION TECHNOLOGY FUNDING FROM BOREALIS, SV...
June 2, 2015 Zachary Brennan The adoption of new technologies related to single-use bioreactors, disposable plastic containers,...
June 1, 2015 Angelo DePalma, Ph.D. Originally conceived as being analogous to what chemists would call a...
June 20, 2014 Gareth MacDonald Protein A will continue to be a major cost for mAb manufacturers...